Skip to content
DataLookout
Menu

NCT04365179

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 6 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jun 30, 2025 to Dec 31, 2027 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 41 words
    • Trial status changed: Unknown → Recruiting
    • Study completion pushed from Aug 30, 2025 to Mar 31, 2028
    • Site details revised
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Primary completion date: Dec 30, 2022 to Jun 30, 2025
    • Trial status: Recruiting to Unknown
    • Study completion date: Dec 30, 2022 to Aug 30, 2025
    v5
  4. Notable Primary and study completion dates: May 30, 2022 to Dec 30, 2022v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 15, 2020 to Jun 18, 2020
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Assessing change in International Working Group (IWG) Criteria to evaluate response to Nerofe Treatment for MDS patients
Timeframe: At Screening (Day 1), at cycle 3 (Day 1) at cycle 5 (Day 1), at cycle 7 (Day 1), at cycle 9 (Day 1) at cycle 11 (Day 1) and at End of Treatment Visit. Cycle length is 28 days. Through study completion, an average of 1 year.
Assessing change in IWG (International Working Group) Criteria to evaluate response to Nerofe Treatment for MDS patients. A calculation of several variables.
Timeframe: At every cycle on Day 1, Day 3, Day 8, Day 10, Day 12, D15, Day 17, Day 19, Day 22, Day 24, Day 26 and Day 28 (cycle length is 28 days), and at End of Treatment Visit, through study completion, an average of 1 year.
Assessing change in European Leukemia Net (ELN) 2017 Criteria to evaluate response to Nerofe Treatment for AML patients
Timeframe: At Screening (Day 1), at cycle 3 (Day 1) at cycle 5 (Day 1), at cycle 7 (Day 1), at cycle 9 (Day 1) at cycle 11 (Day 1) and at End of Treatment Visit. Cycle length is 28 days. Through study completion, an average of 1 year.
Assessing change in ELN 2017 (European Leukemia Net) Criteria to evaluate response to Nerofe Treatment for AML patients. A calculation of several variables.
Timeframe: At every cycle on Day 1, Day 3, Day 8, Day 10, Day 12, D15, Day 17, Day 19, Day 22, Day 24, Day 26 and Day 28 (cycle length is 28 days), and at End of Treatment Visit, through study completion, an average of 1 year.

Arms and interventions

NEROFEExperimental

Dose Level - Nerofe Dose -1 - 6mg/m2 1. \- 12 mg/m2 2. \- 24 mg/m2 3. \- 48 mg/m2 4. \- 96 mg/m2 5. \- 150mg/m2 6. \- 96 mg/m2 7. \- 144 mg/m2 6b - 96 mg/m2 (twice per week)

Drugs: Nerofe

Sites

1 site in 1 country

  • University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer CenterMiami, Florida, United States